Evolving landscape for customized engineered and off-the-shelf immunotherapies in aggressive B-NHL. ADCC: antibody-dependent cell cytotoxicity; ADCP, antibody-dependent cellular phagocytosis; BiTE, bispecific T-cell engager; PD-1, programmed cell death 1; PD-L1, programmed cell death ligand 1.